ADMA

Adma Biologics Inc

$2.43

+0.01 (+0.41%)

quotes and stock data delayed 15 minutes

52 wk hi

52 wk low

1.5

4.16

Cash

$59.7M

Burn Rate (Qtr)

$16.9M

Mkt Cap

$229.8m

Avg Volume

3,804,450

*cash/burn updated:

Q3'20

Company Profile

ADMA is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of Primary Immune Deficiency Disease (PIDD) and certain infectious diseases. ADMA's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. The target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. ADMA’s lead product candidate, RI-002, has completed a Phase III clinical trial in patients with PIDD and has met the primary endpoint. A BLA for RI-002 was accepted by the FDA on September 18, 2015. The company has received U.S. Patent 9,107,906. For more information, please visit the company's website at www.admabiologics.com.